<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30406101</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2296-634X</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>6</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in cell and developmental biology</Title>                <ISOAbbreviation>Front Cell Dev Biol</ISOAbbreviation>            </Journal>            <ArticleTitle>DNMT3B Functions: Novel Insights From Human Disease.</ArticleTitle>            <Pagination>                <MedlinePgn>140</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fcell.2018.00140</ELocationID>            <Abstract>                <AbstractText>DNA methylation plays important roles in gene expression regulation and chromatin structure. Its proper establishment and maintenance are essential for mammalian development and cellular differentiation. DNMT3B is the major <i>de novo</i> DNA methyltransferase expressed and active during the early stage of embryonic development, including implantation. In addition to its well-known role to methylate centromeric, pericentromeric, and subtelomeric repeats, recent observations suggest that DNMT3B acts as the main enzyme methylating intragenic regions of active genes. Although largely studied, much remains unknown regarding how these specific patterns of <i>de novo</i> CpG methylation are established in mammalian cells, and which are the rules governing DNMT3B recruitment and activity. Latest evidence indicates that DNMT3B recruitment is regulated by numerous mechanisms including chromatin modifications, transcription levels, non-coding RNAs, and the presence of DNA-binding factors. DNA methylation abnormalities are a common mark of human diseases involving chromosomal and genomic instabilities, such as inherited disease and cancer. The autosomal recessive Immunodeficiency, Centromeric instability and Facial anomalies syndrome, type I (ICF-1), is associated to hypomorphic mutations in DNMT3B gene, while its altered expression has been correlated with the development of tumors. In both cases, this implies that abnormal DNA hypomethylation and hypermethylation patterns affect gene expression and genomic architecture contributing to the pathological states. We will provide an overview of the most recent research aimed at deciphering the molecular mechanisms by which DNMT3B abnormalities are associated with the onset and progression of these pathologies.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gagliardi</LastName>                    <ForeName>Miriam</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Genetics and Biophysics &quot;Adriano Buzzati Traverso&quot;, CNR, Naples, Italy.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Max Planck Institute of Psychiatry, Munich, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strazzullo</LastName>                    <ForeName>Maria</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Genetics and Biophysics &quot;Adriano Buzzati Traverso&quot;, CNR, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matarazzo</LastName>                    <ForeName>Maria R</ForeName>                    <Initials>MR</Initials>                    <AffiliationInfo>                        <Affiliation>Institute of Genetics and Biophysics &quot;Adriano Buzzati Traverso&quot;, CNR, Naples, Italy.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>22</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Cell Dev Biol</MedlineTA>            <NlmUniqueID>101630250</NlmUniqueID>            <ISSNLinking>2296-634X</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">DNA methylation</Keyword>            <Keyword MajorTopicYN="N">DNMT3B</Keyword>            <Keyword MajorTopicYN="N">ICF syndrome</Keyword>            <Keyword MajorTopicYN="N">cancer</Keyword>            <Keyword MajorTopicYN="N">epigenetics</Keyword>            <Keyword MajorTopicYN="N">gene expression</Keyword>            <Keyword MajorTopicYN="N">human disease</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30406101</ArticleId>            <ArticleId IdType="doi">10.3389/fcell.2018.00140</ArticleId>            <ArticleId IdType="pmc">PMC6204409</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>